An observational study in Frontotemporal Degeneration, Progressive Supranuclear Palsy and Multiple System Atrophy, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-12.
Sponsored by University of Pennsylvania · Observational
Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 26 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 8th largest by enrollment of the 31 observational ones that give a count, is the only one that started in 2003, is one of 31 observational ones, and was the 47th registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
Browse Supranuclear Palsy, Progressive studies →19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
Adam Boxer · Sites in United States
Ages 41–86
Novartis Pharmaceuticals · Sites in United States, Australia, Belgium and 9 more countries
Ages 41–81
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 40–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 18 · Phase 3 5 · Phase 4 2
First in 1995; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 997 is above the median of 200 across 66 observational studies indexed under Supranuclear Palsy, Progressive.
Median enrollment 43 across the 52 interventional studies, 200 across the 31 observational. Of the 53 that completed or were terminated, 9 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 84 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 235 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 109 (69%) have results posted.
University of Pennsylvania has 5 studies filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
9 of the studies in Supranuclear Palsy, Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06355531Ferrer Internacional S.A.A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) | 2026-11 |
| NCT03872102University of Texas Southwestern Medical CenterFacilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging | 2026-12-31 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT04468932Oregon Health and Science UniversityTranscranial Magnetic Stimulation in Progressive Supranuclear Palsy | 2027-04 |
| NCT07863180Prabesh KanelTributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | 2027-05 |
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study that aims to better understand the genetic causes of frontotemporal degeneration (FTD), Multiple Systems Atrophy (MSA), and Progressive Supranuclear Palsy (PSP). It is hoped the information gathered in this study will help lead to better diagnostics and future treatments.
Comparative and longitudinal studies reveal clinical differences between subgroups of patients with frontotemporal dementia (FTD), including Progressive Non-fluent Aphasia (PNFA), Semantic Dementia (SD), patients with a disorder of social comportment and personality (SOC), and non-aphasic patients with executive dysfunction (EXEC). MRI studies of cortical atrophy and fMRI studies show correlated neural defects in FTD subgroups. The investigators will obtain converging evidence from multiple sources to test hypotheses about the neural basis for cognitive functions such as semantic memory, grammatical processing, and social functioning in these FTD subgroups, while improving clinical care for these patients. Recent studies have linked progressive supra nuclear palsy (PSP) and multiple systems atrophy (MSA) to FTD. The investigators will obtain comparable neuropsychological and biomarker data in order to compare these patient groups.
All individuals with a diagnosis of FTD, PSP, or MSA, previously identified by the PI and sub-investigators through other FTD studies (protocol number 702681) and through the PI's extensive FTD clinical practice at the University of Pennsylvania and at Pennsylvania Hospital's Department of Neurology, will be recruited through letters, brochures, and study flyers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention-observation only
Other: None-Observation Only
No intervention-this is an observational study
Progression
Changes over time in MRI and cognitive testing data.
Time frame: This is a natural history study - participants are followed from date of enrollment until death, withdrawl, or funding is no longer available, or until 984 months have passed
Impaired semantic memory in Semantic Dementia (SD).
The impact of cortical atrophy on language processing.
Time frame: This is a natural history study - participants are followed from date of enrollment until death, withdrawl, or funding is no longer available, or until 984 months have passed
Effortful speech in Progressive Nonfluent Aphasia (PNFA)
Speech samples related to cortical atrophy seen on MRI and fMRI studies of verb past tense inflection.
Time frame: This is a natural history study - participants are followed from date of enrollment until death, withdrawl, or funding is no longer available, or until 984 months have passed
Social disinhibition and rule violation in FTD
Relationship of cognitive testing and MRI data and changes over time.
Time frame: This is a natural history study - participants are followed from date of enrollment until death, withdrawl, or funding is no longer available, or until 984 months have passed
Plan to share: Yes — The University of Pennsylvania is a participant in the National Alzheimer's Coordinating Center 's FTLD-NACC initiative to create a national database of data specific to FTD spectrum diseases.The FTLD NACC initiative will enable research centers focusing on FTD spectrum diseases to gather standardized data on their FTLD patients, all of which will be combined into a single database and made freely available to researchers around the world. The FTLD-NACC collects data standardly obtained in this study, including neurocognitive assessments, MRI imaging data, and biomarkers collected through lumbar puncture and blood draw.The FTLD-NACC is designed to facilitate collaborative research and will allow researchers to maximize the use of clinical information and biological material available on frontotemporal degenerative spectrum diseases. Subjects will be able to choose whether or not their research data is shared with the FTD-NACC.
Time frame: As this is an ongoing, longitudinal study, IPD will be available through the duration of the study.
No publications or documents are linked to this record.
Ran from Jul 2003 to primary completion in Jul 2020, 204 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supranuclear Palsy, Progressive →